Compare Incyte Corporation (INCY) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Mega Cap Growth ETF — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Vanguard Mega Cap Growth ETF trades at $90.23. The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | MGK | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $92.06 |
52-Week Low | $81.61 | $70.70 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
MGK trades at $90.30, down 0.36% on the day, with technical indicators showing a bullish trend supported by moving averages but overbought RSI readings. The ETF maintains strong institutional interest, with Bay Colony Advisory Group increasing its stake by 378.7% in the latest quarter. Recent news highlights MGK's superior five-year returns compared to small-cap alternatives, though with higher volatility due to its concentrated mega-cap tech focus.
MGK offers exposure to large-cap growth stocks with a low 0.05% expense ratio, delivering strong historical performance but facing concentration risk in technology sectors. The ETF's outlook remains positive given its track record of beating the S&P 500, though investors should monitor tech sector volatility and potential valuation pressures in mega-cap names.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
